# Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

> **NCT01113476** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 176 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Bevacizumab
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT01113476
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-27
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2022-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01113476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01113476, "Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01113476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*